Role of Tegoprazan in Helicobacter pylori Eradication Therapy

참고문헌 (7)

1. Jung YS, "Systematic review with metaanalysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication", Aliment Pharmacol Ther, 46, pp.106~114 (2017)
2. Li M, "Systematic review with meta-analysis : vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori", Helicobacter, 23, pp.e12495~ (2018)
3. Shinozaki S, "Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy : systematic review and meta-analysis", Digestion, 102, pp.319~325 (2021)
4. Choi Yoon Jin, "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial", Gut and Liver, 16(4), pp.535~546 (2022), 거트앤리버 소화기연관학회협의회[DOI]
5. Hye-Kyung Jung, "Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020", The Korean Journal of Internal Medicine, 36(4), pp.807~838 (2021), 대한내과학회[DOI]
6. Braden B, "The best and worst treatments for Helicobacter pylori", BMJ, 351, pp.h4146~ (2015)
7. Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)

관련 논문AI추천